Personalis reported a 30% year-over-year jump in Q2 revenue, driven by higher pharma testing services and a surge in clinical tests following Medicare reimbursement expansion. The company also noted Medicare approval for its NeXT Personal assay for monitoring response in stage II–III triple-negative or HER2-positive breast cancer receiving neoadjuvant therapy.